PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
April 27 2022 - 9:00AM
Business Wire
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company
focused on developing cellular therapies for cancer and diabetes
using its signature live-cell encapsulation technology,
Cell-in-a-Box®, announced today that the management team will be
attending the 15th International Conference on Advanced
Technologies and Treatments for Diabetes (ATTD) held April 27-30,
2022, in Barcelona, Spain. ATTD is a scientific conference that was
established in 2008. The meetings at the conference have become the
most renowned forum worldwide for presenting developments in new
diabetes technologies and treatments.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said,
“This annual conference is where clinicians, diabetes care
providers, researchers, industry leaders and investors come
together to share knowledge and develop collaborations. As we
continue to broaden our product portfolio, the development of a
treatment for Type 1 and insulin-dependent Type 2 diabetes that can
essentially serve as an ‘artificial pancreas’ is vitally important
to PharmaCyte. Our live-cell encapsulation-based treatment offers
real hope for future development in the field of diabetes.”
Main topics being discussed during the conference include
decision support systems, data and artificial intelligence based
decision support systems, closed-loop systems and algorithms,
artificial pancreas, insulin pumps, glucose sensors, implantable
pumps and sensors, new insulin analogs and new insulin delivery
systems, devices focused on diabetic preventions, informatics in
the service of medicine; telemedicine, software and other
technologies, advanced medical technologies to be used in hospitals
and more.
In addition to attending presentations and discussions by
distinguished professionals in the field, PharmaCyte’s management
team will meet with members of its International Diabetes
Consortium to launch its new diabetes endeavors.
To learn more about PharmaCyte’s pancreatic cancer treatment and
how it works inside the body to treat locally advanced inoperable
pancreatic cancer, we encourage you to watch the company’s
documentary video complete with medical animations at:
https://www.PharmaCyte.com/Cancer
About PharmaCyte Biotech
PharmaCyte Biotech, Inc. is a biotechnology company developing
cellular therapies for cancer and diabetes based upon a proprietary
cellulose-based live cell encapsulation technology known as
“Cell-in-a-Box®.” This technology is being used as a platform upon
which therapies for several types of cancer and diabetes are being
developed.
PharmaCyte’s therapy for cancer involves encapsulating
genetically engineered human cells that convert an inactive
chemotherapy drug into its active or “cancer-killing” form. For
pancreatic cancer, these encapsulated cells are implanted in the
blood supply to the patient’s tumor as close as possible to the
site of the tumor. Once implanted, a chemotherapy drug that is
normally activated in the liver (ifosfamide) is given intravenously
at one-third the normal dose. The ifosfamide is carried by the
circulatory system to where the encapsulated cells have been
implanted. When the ifosfamide flows through pores in the capsules,
the live cells inside act as a “bio-artificial liver” and activate
the chemotherapy drug at the site of the cancer. This “targeted
chemotherapy” has proven effective and safe to use in past clinical
trials and we believe results in little to no treatment related
side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent
Type 2 diabetes involves encapsulating a human cell line that has
been genetically engineered to produce and release insulin in
response to the levels of blood sugar in the human body. The
encapsulation of the cell line will be done using the
Cell-in-a-Box® technology. Once the encapsulated cells are
implanted in a diabetic patient, we anticipate that they will
function as a “bio-artificial pancreas” for purposes of insulin
production.
Safe Harbor
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that express the current beliefs and expectations of the management
of PharmaCyte. Any statements contained herein that do not describe
historical facts are forward-looking statements that are subject to
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from those
discussed in such forward-looking statements. Factors that could
affect our actual results include our ability to raise the
necessary capital to fund our operations and to find partners to
supplement our capabilities and resources, our ability to
satisfactorily address the issues raised by the FDA in order to
have the clinical hold on our IND removed, as well as such other
factors that are included in the periodic reports on Form 10-K and
Form 10-Q that we file with the U.S. Securities and Exchange
Commission. These forward- looking statements are made only as of
the date hereof, and we undertake no obligation to update or revise
the forward-looking statements, except as otherwise required by
law, whether as a result of new information, future events or
otherwise.
More information about PharmaCyte Biotech can be found at
www.PharmaCyte.com. Information may also be obtained by contacting
PharmaCyte’s Investor Relations Department.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220427005443/en/
Dr. Gerald W. Crabtree PharmaCyte Biotech, Inc. Investor
Relations Department Telephone: 917.595.2856 Email:
Info@PharmaCyte.com
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Apr 2023 to Apr 2024